How to Find the Right Biologics CDMO

Searching for a biologics CDMO can produce a long list of companies very quickly.

That does not mean those companies are interchangeable.

One biologics manufacturer may focus heavily on early clinical development. Another may specialize in large-scale commercial production. Facilities may use different expression systems, bioreactor configurations, purification equipment, analytical capabilities, and manufacturing scales.

So the useful question is not simply:

Which companies manufacture biologics?

It is:

Which biologics CDMOs and facilities appear to fit this particular program?

That distinction should shape the entire sourcing process.

A biologics CDMO is a contract development and manufacturing organization that supports development or production of biological drug products.

Depending on the company and facility, services may include:

• cell line development
• process development
• upstream processing
• downstream purification
• analytical development
• formulation development
• technology transfer
• GMP drug substance manufacturing
• drug product manufacturing
• fill finish
• stability testing
• clinical manufacturing
• commercial manufacturing

Some biologics CDMOs provide an integrated development-to-manufacturing offering.

Others specialize in a narrower portion of the process.

Neither model is automatically better.

The right structure depends on what the sponsor needs.

“Biologics” is a broad manufacturing category.

The requirements of a monoclonal antibody program may differ substantially from those of a recombinant protein, enzyme, vaccine, or other biologic.

Before comparing manufacturers, define the product and process requirements as clearly as possible.

Important questions may include:

• What type of biologic is being developed?
• What expression system is being used?
• Is the process already established?
• What development work remains?
• What manufacturing scale is required?
• What stage is the program in?
• Is drug substance, drug product, or both required?

Those answers help narrow a large biologics CDMO market into a more relevant group of manufacturers.

A biologics CDMO's experience with the relevant expression system can matter significantly.

Depending on the product, manufacturing may involve mammalian, microbial, or other expression systems.

A facility that regularly supports one type of production platform may not necessarily be appropriate for another.

Sponsors should therefore look beyond a general statement such as:

“We manufacture biologics.”

The more useful question is whether the proposed facility supports the manufacturing platform actually used by the program.

Upstream processing covers the production stage in which cells or microorganisms are grown to produce the biological product.

Depending on the project, sponsors may need to understand:

• available bioreactor systems
• production scale
• single-use or stainless-steel configurations
• fed-batch or other process approaches
• cell culture capabilities
• process-development support
• scale-up experience

The relevant questions will depend on the program.

A facility with impressive biologics infrastructure may still be poorly aligned if the available equipment or production scale does not fit the process.

Producing the molecule is only part of biologics manufacturing.

The product also needs to be recovered and purified.

Sponsors should investigate whether the CDMO can support the downstream operations required by the process.

Depending on the program, that may include:

• harvest and clarification
• chromatography
• filtration
• viral clearance
• concentration
• buffer exchange
• bulk drug substance handling

Again, the objective is not to find the CDMO with the longest equipment list.

It is to determine whether the relevant facility appears capable of supporting the actual process.

Some biotech teams arrive with a mature manufacturing process.

Others need substantial development work before GMP manufacturing can begin.

That difference can materially affect CDMO selection.

A sponsor may need help with:

• process optimization
• scale-up
• media or feed development
• purification development
• analytical methods
• formulation
• process characterization

If substantial development work remains, the quality and depth of the CDMO's development capabilities may matter as much as its manufacturing infrastructure.

Biologics programs can require significant analytical support throughout development and manufacturing.

Sponsors should understand which analytical activities the CDMO can perform internally and which may be outsourced.

Relevant areas can include:

• identity
• purity
• potency
• concentration
• product-related impurities
• process-related impurities
• stability
• release testing

The exact analytical strategy is product-specific.

During sourcing, the important question is whether the manufacturer's analytical capabilities appear compatible with the program's needs.

Biologics manufacturing scale can vary substantially.

An early clinical program may require relatively modest production compared with a late-stage or commercial program.

Bigger is not automatically better.

A facility built primarily around large commercial campaigns may not be the most practical option for a small early-stage program.

Likewise, a facility optimized for early development may not provide the long-term scale a sponsor expects to require later.

Sponsors should consider both current needs and the likely manufacturing path ahead.

The best CDMO for a Phase I program is not necessarily the best partner for commercial production.

Early-stage sponsors may place more emphasis on:

• development support
• flexibility
• smaller batch sizes
• responsive technical teams
• speed of execution

Commercial programs may place greater emphasis on:

• manufacturing scale
• process robustness
• validation
• supply reliability
• long-term capacity
• lifecycle management

The stage of the program should therefore be part of the search criteria from the beginning.

Some CDMOs can support both biologics drug substance and final drug product manufacturing.

Others specialize in one side of the process.

An integrated provider may reduce the number of transfers between organizations.

A specialized model may allow the sponsor to select different partners with deeper expertise in each area.

There is no universal answer.

Sponsors should decide whether they want:

one integrated biologics CDMO

or

separate drug substance and drug product partners

based on the needs of the program.

Large biologics CDMOs may operate multiple sites.

Those facilities can differ in:

• expression systems
• equipment
• scale
• manufacturing services
• regulatory history
• development-stage focus
• geography

A parent company's overall capabilities do not necessarily describe the facility that would support your project.

Facility-level research is therefore an important part of biologics CDMO selection.

Regulatory history should be considered alongside technical fit.

Sponsors may want to review facility-level inspection history, including available FDA Form 483 information.

It is information that may warrant further review.

Sponsors should consider the facility involved, observations made, timing, subsequent history, and relevance to the proposed manufacturing work.

Formal quality and regulatory diligence remains the sponsor's responsibility.

Biologics manufacturing capacity can become a major constraint.

A facility may be technically ideal but unavailable within the required timeline.

Once a biologics CDMO appears technically relevant, sponsors should begin asking about:

• project kickoff
• process-development availability
• technology-transfer timing
• engineering runs
• GMP manufacturing slots
• analytical lead times
• follow-on batch scheduling

Availability can change quickly.

Current capacity should always be confirmed directly with the CDMO.

A structured comparison might include:

Using the same criteria across manufacturers makes it easier to understand why one CDMO may fit the project better than another.

Before investing time in a full proposal, a few direct questions can show whether a biologics manufacturer is worth advancing:

• Which expression systems and molecule types has this specific facility manufactured?
• Can upstream and downstream work be performed at the scale the next phase requires?
• Is process development handled at the same site as GMP manufacturing?
• Which analytical methods are performed in-house, and which are outsourced?
• Is drug product or fill finish available, or will a second partner be needed?
• What does near-term capacity look like for the program's timeline?

For biologics programs, PCN lets sponsors describe the molecule, expression system, stage, and scale, then compare CDMO facilities on capabilities, equipment, and FDA Form 483 context before requesting a structured introduction. Narrower programs are covered in the monoclonal antibody CDMO guide and the ADC CDMO guide.

PCN does not replace formal technical, quality, regulatory, or vendor qualification diligence.